B&K (2396) Stock Overview
Operates as a biopharmaceutical company developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
2396 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
B&K Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$4.80 |
| 52 Week High | HK$37.20 |
| 52 Week Low | HK$4.80 |
| Beta | 0 |
| 1 Month Change | -18.23% |
| 3 Month Change | -40.22% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2396 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -7.5% | -4.7% | -2.6% |
| 1Y | n/a | -15.3% | 3.5% |
Return vs Industry: Insufficient data to determine how 2396 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 2396 performed against the Hong Kong Market.
Price Volatility
| 2396 volatility | |
|---|---|
| 2396 Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 16.0% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 2396 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: Insufficient data to determine 2396's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 100 | Kelong Wang | www.huarenshengwu.com/en/ |
B&K Corporation Limited operates as a biopharmaceutical company developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities in China. The company primarily focuses on the discovery, development, and commercialization of therapies for wound healing, currently platelet-derived growth factor (“PDGF”) drugs. The company’s pipeline comprised two Core Products including Pro-101-1 for the treatment of deep second-degree thermal burns, which has completed the statistical data analysis for Phase IIb clinical trial, and for the treatment of superficial second-degree thermal burns,; and Pro-101-2 for the treatment of diabetic foot ulcers.
B&K Corporation Limited Fundamentals Summary
| 2396 fundamental statistics | |
|---|---|
| Market cap | HK$564.76m |
| Earnings (TTM) | -HK$242.08m |
| Revenue (TTM) | HK$604.66k |
Is 2396 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2396 income statement (TTM) | |
|---|---|
| Revenue | CN¥522.00k |
| Cost of Revenue | CN¥41.00k |
| Gross Profit | CN¥481.00k |
| Other Expenses | CN¥209.47m |
| Earnings | -CN¥208.98m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.78 |
| Gross Margin | 92.15% |
| Net Profit Margin | -40,035.25% |
| Debt/Equity Ratio | 0% |
How did 2396 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/12 18:44 |
| End of Day Share Price | 2026/06/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
B&K Corporation Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.